In conclusion, DW18134 could potentially treat acute peritonitis by reducing macrophage infiltration, regulating the NF-κB signaling pathway through targeting IRAK4, and subsequently inhibiting the expression of inflammatory cytokines to ameliorate pathological injury. Here, NFKB1 is linked to peritonitis.